Important Dates for the CRISPR Medicine Conference 2024
Before the Event:
- September 1st, 2023: Registration & abstract submissions open
- January 12th, 2024: Early bird registration deadline
- January 24th, 2024: Abstract submission deadline
- February 16th, 2024: Oral and poster notifications & final programme available
- April 21st, 2024: Registration deadline
- April 22nd, 2024: Abstract publication in the CRISPR Medicine News portal
Event:
- April 22nd, 2024: Virtual event
- April 23-25th, 2024: In-person event in Copenhagen, Denmark
Welcome
The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25th April 2024 (virtual event 22nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.
This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.
You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 20,000 readers per month.
Once you have registered, you will be able to explore the content and see the list of participants.
If you have any questions, please refer to our FAQ section or contact CRISPRMED24 staff at info@crisprmedicineconference.com
**CRISPRMED24 Newsletter - Sign up here**
Preliminary Program
Keynote Speaker
Luigi Naldini
San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).
For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.
Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.
Sponsors
Confirmed Speakers
Alessia Cavazza
University College London, United Kingdom
Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.
André Choulika
Cellectis
CEO at Cellectis.
André Cohnen
Bayer AG
Head of Genomic Medicine at Bayer.
Andrew Bellinger
Verve Therapeutics
CSO at Verve Therapeutics and Co-Founder at Corner Therapeutics
Angelo Lombardo
San Raffaele - Telethon Institute for Gene Therapy, Italy
Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget) and Professor at the Vita-Salute San Raffaele University in Milano, Italy. Co-founder of Chroma Medicine.
Anna Cereseto
University of Trento, Italy
Professor. and Vice-Director of Department at University of Trento, and Co-Founder of Alia Therapeutics.
Avencia Sanchez-Mejias
INTEGRA Therapeutics
CEO and Co-founder at INTEGRA Therapeutics.
Ayal Hendal
Bar-Ilan University, Israel
Principal Investigator and Group leader at Bar-Ilan University, Israel.
Ben Kleinstiver
Harvard Medical School and Massachusetts General Hospital
Assistant Professor at the Center for Genomic Medicine, Harvard Medical School. MGH Research Scholar at Massachusetts General Hospital.
Bernhard Schmierer
Karolinska Institutet, Sweden
Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.
Christian Groendahl
SNIPR Biome
CEO and Co-founder at SNIPR Biome.
Hao Wu
Full Circles Therapeutics/Stellate DNA, USA
Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA.
Jan Gorodkin
University of Copenhagen, Denmark
Prof. and Group leader at University of Copenhagen, Denmark.
Jan Nelis
Ariya Bio
Co-Founder and Project Lead at Ariya Bio.
Karim Benabdellah
Fundación Pública Andaluza Progreso y Salud, Spain.
Senior Scientist at the GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain.
Karina Thorn
Novo Nordisk
Corporate Vice President, PhD, RNA and Gene Therapies, Global Research Technologies at Novo Nordisk.
Kevin Holden
Synthego
Head of Science & Applied Research at Synthego.
Laura Sepp-Lorenzino
Intellia Therapeutics
Executive Vice President and Chief Scientific Officer at Intellia Therapeutics.
Manuel Kaulich
Goethe University Frankfurt, Germany
Prof. at Goethe University Frankfurt, Germany and CSO at Vivlion.
Marcello Maresca
AstraZeneca AB
Senior Director of Genome Engineering Team at AstraZeneca.
Marianne Carlon
Catholic University (KU) Leuven, Belgium
Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine.
Google Scholar ORCIID LinkedIn BREATHE Webpage KU Leuven Webpage
Paula Rio
CIEMAT/CIBERER/IIS-FJD, Universidad Autónoma de Madrid
Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid.
Pia Johansson
Lund University, Sweden
Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.
Rasmus O. Bak
Aarhus University, Denmark
Ass. Prof. at the Department of Biomedicine at Aahrus University and Co-Founder of UNIKUM Therapeutics.
Samantha Maragh
National Institute of Standards & Technology, USA
Leader of the Gene Editing Program at the National Institute of Standards & Technology.
Simon Reed
Broken String Biosciences
Co-Founder and CSO at Broken String Biosciences.
Stefano Stella
Ensoma
Vice-President of Gene Editing at Ensoma, Founder and Chief Technology Officer at Twelve Bio, Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.
Toni Cathomen
University of Freiburg, Germany
Prof. and Director at the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg.
Waseem Qasim
UCL Great Ormond Street Institute of Child Health, UK
Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health
Xavier Duportet
Eligo Bioscinece
CEO and Co-founder at Eligo Bioscience.
Yonglun Luo
Aarhus University, Denmark
Prof. of Gene and Stem Cell Technology at Aarhus University, Denmark and Executive Director at the Lars Bolund Institute of Regenerative Medicine, China.
Scientific Committee
· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN
Organising Committee
· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News
Attendees (confirmed) - Companies and Organisations
Attendees (confimed) - Investors
List of reviewers
Coming soon!
Location
Copenhagen, Denmark
Registration period
August 1, 2023 - 00:00 until April 21, 2024 - 18:00
Submission period
August 1, 2023 - 12:00 until January 24, 2024 - 18:00
Contact us
If you have any questions, please contact info@crisprmedicineconference.com .